-605
Days Left
Lead Plaintiff Deadline: October 04, 2021
See If You Qualify For Monetary Reward
Please Upload related files below
Fill in below.
Looking for more?
30
Nov 2020
23
Jul 2021
(i) the sulopenem New Drug Application (“NDA”) lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
In order to be included in the lawsuit, you must have incurred a loss on shares of Iterum purchased or acquired during the class period listed above.
If you suffered a loss in Iterum during the relevant time frame, you have until October 04, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.